News

CLOSED Director, Product Development & Technical Affairs – ProTA Therapeutics Pty Ltd

ProTA Therapeutics is a newly established Australian private company developing immunotherapy based treatments for food allergy. The company’s lead product based on technology spun out of the Murdoch Childrens Research Institute, is under development as a treatment for…

CLOSED MD / CEO – Neurosciences Victoria

Neurosciences Victoria (NSV) is dedicated to the continued development of the world-class neuroscience cluster in Melbourne, encouraging international collaborations and partnerships leading to strategic investment in the gap between academic discovery research and commercial development. Working closely with the Board,…

Opthea Successfully Completes Placement and Institutional Entitlement Offer

• Placement and Institutional Entitlement Offer successfully completed, raising approximately A$42million with strong support from both existing and new institutional and sophisticated investors • Retail Entitlement Offer will open on Monday, 10 April 2017 and closes at 5:00pm…

Bionic Vision Technologies raises $US18m from State Path Capital, China Huarong

The Australian university-owned company in the race to develop a bionic eye to restore sight has been saved from its own near plunge into darkness after raising $US18 million ($23.6 million) from Chinese investors including the nephew of Hong…

The Medical Technologies and Pharmaceuticals (MTP) Roadmap – unlocking future growth opportunities for Australia

A changing global landscape The global MTP industry is on the cusp of enormous growth globally due to a range of factors including ageing populations, the growth of emerging markets seeking better health services and unprecedented innovation in…

New abilities to enhance cancer research at the Australian Synchrotron

It gave me great pleasure to today unveil the newest research tool that Australian scientists and researchers have in the fight against cancer. The Australian Synchrotron’s new multi-million dollar Australian Cancer Research Foundation (ACRF) Detector will fast-track new…

Opthea Launches A$45 Million Financing to Progress OPT- 302 Expanded Clinical Development

Opthea Limited (ASX:OPT) (“Opthea”), a developer of novel biologic therapies for the treatment of eye diseases, today announced the launch of an entitlement offer and institutional placement (collectively the “Offer”) to raise approximately A$45 million. Proceeds from the…

Lab-grown mini-organs help model disease, test new drugs

To the naked eye, the little globs of cells are undifferentiated masses, smaller than sesame seeds. Put them under a microscope, though, and these lab-grown miniature organs show striking complexity: the tiny tubules of a kidney, the delicate…

Australia’s new National Science Statement! The Australian Government long-term vision for science research and policy making

The Australian Government’s National Innovation and Science Agenda identified science as one of the critical elements for Australia to deliver new sources of growth, maintain high‑wage jobs and seize the next wave of economic prosperity. Science—including the natural,…

Easing the pain of global expansion

Two years after going global, Australian healthcare company Medical Developments International (MDI) which manufactures the acute pain killer Penthrox (commonly known as ‘the green whistle’) has opened a new facility in Melbourne Assisted by CSIRO, MDI has seen…

The US drug pricing debate: Managing risks to results

EY report on drug pricing The unsustainable trajectory of the health care spending in the US is generating much dialog and consternation across a variety of stakeholders including governments, industry, media academic think-tanks and the general public. Prescription…

New Director of Bio 21 announced

Professor Michael Parker has been appointed as the new Director of the University of Melbourne’s Bio 21 Molecular Science and Biotechnology Institute. One of Australia’s leading protein structural biologists, Prof Parker will take up the role as part…

Home

News & opinion

Member Directory

Events